$13.29
-0.30%Burning Rock Biotech Limited develops and sells cancer therapy selection tests in the People's Republic of China and the United States. It operates in three segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services. The company offers next-generation sequencing (NGS)-based tissue, liquid biopsy cancer therapy selection, and prognosis prediction tests for various cancer types, including lung cancer, gastrointestinal cancer, prostate cancer, breast cancer, lymphomas, thyroid cancer, colorectal cancer, ovarian cancer, pancreatic cancer, and bladder cancer using tissue and liquid biopsy samples.
Quality against peers; 50 is the peer median.
Showing the last 4 periods. Pro adds the full annual and quarterly history and 20+ more metrics to chart.
The latest fiscal year and quarter, each against the same period a year earlier, from SEC filings.
From the notes to the annual report for fiscal 2025, ending December.
Fundamentals: fiscal year to Dec 2025. This company files annual reports only.
IM industry median · SM sector median: the typical company the value is compared with. The /100 is its score against those peers.
The companies closest in size in Diagnostics & Research (filled from its sector when there are few), with the median and rank across all 45 in the industry.